Annual Congress of the European Association for Cancer Research (EACR) 2024

Rotterdam Ahoy, Ahoyweg 10, 3084 BA Rotterdam

The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024) is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations.

Meet the NanoString team by visiting booth #23.

Would you like to book a meeting with a team member? Please contact Irene Yujnovsky.

NanoString Symposium | Monday 10th June | 13:15 – 14:00 PM | Port Room

Explore the current landscape and future prospects of spatial biology at our upcoming symposium. We will reveal the latest advancements in product technology including the GeoMx® IO Proteome Atlas, an innovative solution allowing the profiling of over 570 proteins within precise tissue compartments.

Furthermore, Prof. Jamieson will provide an in-depth analysis of his latest results including the use of the  CosMx™ Human 6K Discovery Panel, a pioneering solution for profiling over 6,000 genes at single-cell resolution and preserving the biological context. Join us on June 10th to stay updated on these exciting developments!

  • 13:15-13:20: Introduction by Irene Yujnovsky, PhD., Sr. Regional Marketing Manager, NanoString.​
  • 13:20-13:40: Uncovering Spatial Insights in Cancer Research through High-Plex Spatial Multi-Omics by Alyssa Rosenbloom, PhD., Associate Director, R&D, NanoString​
  • 13:40-14:00: Multi-omic, multi-scale Characterisation of Colorectal Cancer Defines Spatiotemporal Patterns and pathways by Nigel Jamieson, PhD., University of Glasgow​

NanoString EACR posters

Poster #Abstract
SessionDate & TimePoster TitlePresenterProduct
350EACR2024-0968Translational ResearchJune 11th
Constructing comprehensive single-cell spatial atlases across multiple FFPE human tissues using a universal 6,000-plex RNA panelRudy van EijsdenCosMx SMI
352EACR2024-0972  Translational ResearchJune 11th
Comparative biological discoveries between colon cancer and diseased tissues using a novel spatial multiomic approach and a comprehensive Immuno-Oncology Proteome Atlas and Whole Transcriptome AtlasIrene YujnovskyGeoMx DSP
397EACR2024-0889  Tumour BiologyJune 12th 18:40-20:15Ultra highplex spatial proteomic and transcriptomic analysis of the head and neck cancer tumour microenvironmentAlyssa RosenbloomGeoMx DSP

Become a Guardian of the ‘Omics Galaxy Defenders of Plex and Gene Expression!

As part of the NanoString Guardian of the ‘Omics Galaxy photo contest, post your superhero photo onto your social media channels with #NanoString #EACR2024, all participants will be entered into a raffle to win our grand prize of a Polaroid camera bundle.

Take a selfie and let AI create your NanoString Guardian of the Omics Galaxy social media post to enter a raffle to win a Polaroid Instant Camara Bundle (terms and conditions apply).

Scan the QR code on the right to Get Your Superhero Photo


Alyssa Rosenbloom, PhD

Alyssa Rosenbloom, PhD

Associate Director Research, NanoString

Circular portrait of Nigel Jamieson

Nigel Jamieson MD PhD

Clinical Senior Lecturer and Consultant HPB Surgeon; Clinician Scientist, Cancer Research UK; School of Cancer Sciences, Glasgow Royal Infirmary, University of Glasgow

Nigel Jamieson is a Clinical Senior Lecturer within the Institute of Cancer Sciences and an Honorary Consultant HPB surgeon at Glasgow Royal Infirmary. He has contributed to over 130 peer reviewed publications and has an active role in the development and management of the Precision-Panc platform; his laboratory group focuses on the interaction between the immune microenvironment and chemotherapy in the tumors of patients with pancreatic cancer and has established a spatial transcriptomic facility characterizing multiple malignancies, premalignant lesions, and inflammatory conditions. He works closely with Pancreatic Cancer UK and is part of a national group aiming to standardize care for patients with pancreatic cancer across the UK.